Amgen and Johnson & Johnson have come to a truce a two-and-a-half year battle over marketing of rival oncology products.
Amgen has agreed to pay $200 million to settle an antitrust lawsuit by Johnson & Johnson over discounts and incentives that Amgen offered to cancer clinics buying its Aranesp, Neupogen and Neulasta. J&J, which makes competitor [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment